Relief of intractable pruritus with romidepsin in patients with cutaneous T-cell lymphoma: A series of four cases

Keyphrases

• Adverse Events 20%
• Antipruritic Effect 20%
• Chronic Pruritus 100%
• Cutaneous T-cell Lymphoma 100%
• Daily Activities 20%
• Dose Adjustment 20%
• Heterogeneous Groups 20%
• Histone Deacetylase Inhibitor (HDACi) 20%
• Itch Therapy 20%
• Lymphoma Therapy 20%
• Maintenance Treatment 20%
• Non-Hodgkin Lymphoma 20%
• Non-responders 20%
• Pruritus 60%
• Quality of Life 20%
• Rare Group 20%
• Romidepsin 100%
• Systemic Therapy 20%

Medicine and Dentistry

• Adverse Event 16%
• Antipruritic 16%
• Cutaneous T Cell Lymphoma 100%
• Histone Deacetylase Inhibitor 16%
• Maintenance Therapy 16%
• Non-Hodgkin Lymphoma 16%
• Pruritus 100%
• Quality of Life 16%
• Romidepsin 100%
• Systemic Therapy 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Adverse Event 16%
• Antipruritic Agent 16%
• Cutaneous T Cell Lymphoma 100%
• Histone Deacetylase Inhibitor 16%
• Nonhodgkin Lymphoma 16%
• Pruritus 100%
• Romidepsin 100%